Online inquiry

IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11404MR)

This product GTTS-WQ11404MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets PDGFRA gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001347829.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5156
UniProt ID P16234
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ11404MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8811MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IBI-308
GTTS-WQ4081MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BI 836
GTTS-WQ587MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 6A3-IgG4
GTTS-WQ2671MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 655
GTTS-WQ5353MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ8393MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA HS006
GTTS-WQ2501MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 212
GTTS-WQ4238MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BIIB031
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW